Antimicrobial evaluation

Statens Serum Institut (SSI) has state of the art laboratories and animal facilities. We offer design, planning and execution of in vitro and in vivo studies.

SSI has developed experimental infection models for the purpose of evaluating antimicrobial drugs. These models are ideal for efficacy screening of new compounds in the discovery phase, proof of concept, as well as for pharmacokinetic and pharmacodynamic studies. Advanced mathematical PK/PD modelling is also used as an integrated part of such studies.

In vitro evaluation of antimicrobials

  • Determination of minimum inhibitory concentrations (MIC)
  • Time kill activity

In vivo efficacy studies in murine infection models

  • Peritonitis/Sepsis
  • Thigh infection
  • Urinary tract infection
  • Skin infection
  • Pneumonia
  • Fungal sepsis

In vivo pharmacology

  • Pharmacokinetics (PK)
  • Pharmacodynamics (PD)
  • Mathematical PK/PD modelling
  • Dosing recommendations

Antimicrobial susceptibility testing

  • Evaluation of methods for antimicrobial susceptibility testing
  • Evaluation of new in vitro diagnostics
  • Typing of microbial strains
  • Characterization of mechanisms of antimicrobial resistance

Downloads

Temaer

Assay design and development

Assay design and development

At Statens Serum Institut (SSI) we have a long-term experience in quantitative detection of virus and virus-specific antibodies using the haemagglutination (HA) assay and the haemagglutination inhibition (HAI) assay.
Detection of viruses

Detection of viruses

The unbiased DNA microarray testing has emerged as a promising new technology for broad-spectrum virus detection (metagenomic diagnostic), making it possible to test for the presence of thousands of viruses simultaneously without having a clear predetermination of what to look for. This is convenient e.g. in diagnostic for disease syndromes, in hematological patients, in travellers with exotic virus, and difficult to diagnose patients. We have developed a microarray platform, Pan-Virus Array.
Development of monoclonal and polyclonal antibodies

Development of monoclonal and polyclonal antibodies

Statens Serum Instititut (SSI) has about 35 years of experience in developing and producing monoclonal antibodies and more than 100 years of experience in production of polyclonal antibodies. SSI uses different species of animals for this purpose.
Experimental infection models

Experimental infection models

SSI has state of the art laboratories and animal facilities. We offer design, planning and execution of in vivo experimental infection studies. These models can be used for studying host pathogen interactions, host responses, bacterial virulence and antibiotic treatment.
Carina Vingsbo Lundberg

Contact

Carina Vingsbo Lundberg , Bakterier, parasitter og svampe / Antibiotikaresistens og Præklinisk Forsk
T. +45 32688209 @. cvl@ssi.dk View profile